Allogene Therapeutics (ALLO) Current Assets (2018 - 2026)

Allogene Therapeutics has disclosed Current Assets across 9 years of filings, most recently posting $273.3 million for Q1 2026.

• Current Assets for Q1 2026 came in at $273.3 million, down 6.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $273.3 million (down 6.27% YoY), and the FY2025 annual result was $257.7 million, down 15.04% from the prior year.
• Current Assets came in at $273.3 million for Q1 2026 at Allogene Therapeutics, up from $257.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $569.1 million in Q3 2022 to a low of $257.7 million in Q4 2025.
• The 5-year median for Current Assets is $457.1 million (2024), against an average of $401.4 million.
• Across the five-year window, Current Assets advanced 13.17% in 2022 and sank 38.17% in 2025, its largest moves.
• Allogene Therapeutics' Current Assets stood at $528.8 million in 2022, then decreased by 13.18% to $459.1 million in 2023, then tumbled by 33.92% to $303.4 million in 2024, then slipped by 15.04% to $257.7 million in 2025, then gained by 6.03% to $273.3 million in 2026.
• The last three Current Assets figures came in at $273.3 million (Q1 2026), $257.7 million (Q4 2025), and $260.7 million (Q3 2025), per Business Quant data.